Anti-Human VEGF-A (Brolucizumab Biosimilar)
英诺赛图(InnoCyto)的 Anti-Human VEGF-A (Brolucizumab Biosimilar)(克隆 Brolucizumab) 为人源 IgG1 抗体,靶向 VEGF-A。提供 1 mg、5 mg、20 mg 规格,目录价 ¥3,390 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human VEGF-A (Brolucizumab Biosimilar)(克隆 Brolucizumab) 为人源 IgG1 抗体,靶向 VEGF-A。提供 1 mg、5 mg、20 mg 规格,目录价 ¥3,390 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
501101 | 1 mg | ¥3,390
501102 | 5 mg | ¥8,136
501103 | 20 mg | ¥26,442
Product Details
Application|Neutralization, Intracellular Flow cytometry, animal model study
Product Description|Anti-Human VEGF-A (Brolucizumab Biosimilar)
Regulatory Status|RUO
Species specificity|Human
Min Sample Size|1 mg
Storage Conditions|4ºC
Maximal Shelf Life|12 months
See All Formats|Clone Brolucizumab
Background Information
Brolucizumab is a humanized single-chain antibody fragment (scFv) engineered to bind vascular endothelial growth factor A (VEGF-A) with high specificity and affinity. Structurally, it differs from conventional full-length antibodies in that it consists of only the variable regions of the heavy (VH) and light (VL) chains connected by a flexible peptide linker, forming a single polypeptide chain rather than a whole immunoglobulin molecule. The absence of constant (Fc) regions significantly reduces its molecular mass, approximately 26 kilodaltons (kDa), making Brolucizumab one of the smallest antibody-derived therapeutic proteins developed for VEGF inhibition.
The functional activity of Brolucizumab centers on its ability to bind with high affinity to all major isoforms of VEGF-A, including VEGF121, VEGF165, and VEGF189. Through its antigen-binding site, formed by complementarity-determining regions (CDRs) within the VH and VL domains, Brolucizumab effectively neutralizes VEGF-A, preventing its interaction with surface receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR) on endothelial cells. Blocking this ligand–receptor interaction inhibits receptor dimerization and downstream signaling cascades, including those mediated by the MAPK and PI3K-AKT pathways, which are involved in endothelial cell proliferation, migration, and vascular permeability.
Structurally optimized for stability and solubility, Brolucizumab maintains a monomeric form under physiological conditions and exhibits strong biophysical integrity despite lacking glycosylation. The small molecular size facilitates efficient tissue penetration and high molar binding capacity per administered volume. Overall, Brolucizumab exemplifies a rationally designed antibody fragment, combining the precise antigen recognition of conventional antibodies with the compactness and pharmacokinetic advantages of a streamlined single-chain variable fragment architecture.
Data Sheets
Cat # Size Price Quantity 5011011 mg Add to Cart5011025 mg Add to Cart50110320 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human VEGF-A (Brolucizumab Biosimilar)(501101)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-vegf-a-brolucizumab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human VEGF-A (Brolucizumab Biosimilar)(501101). 产品目录. https://www.suprotek.cn/products/item/anti-human-vegf-a-brolucizumab-biosimilar.html
@misc{biocsp_item_anti_human_vegf_a_brolucizumab_biosimilar,
title = {Anti-Human VEGF-A (Brolucizumab Biosimilar)(501101)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-vegf-a-brolucizumab-biosimilar.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源